A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates.
